Virus Diseases Clinical Trial
Official title:
Safety and Immunogenicity Study of GSK Biologicals' Investigational Recombinant Chimpanzee Adenovirus Type 3-vectored Ebola Zaire Vaccine (GSK3390107A) in Children in Africa
The purpose of this study is to assess the safety and reactogenicity of a single IM dose of
the GSK3390107A (ChAd3 EBO-Z) vaccine, overall and in children aged 1 to 5, 6 to 12, and 13
to 17 years, separately.
Considering the risk of exposure to Ebola and the potential (based on animal data) for the
investigational GSK3390107A (ChAd3-EBO-Z) vaccine to afford at least partial protection, all
children in the study will receive the investigational GSK3390107A (ChAd3 EBO-Z) vaccine. The
children in the Group GSK3390107A+Nimenrix will receive the investigational GSK3390107A
(ChAd3-EBO-Z) vaccine at Day 0 of the study, whereas the children in the Group
Nimenrix+GSK3390107A will receive Nimenrix at Day 0 (as a control). At Month 6, the children
in the Group Nimenrix+GSK3390107A will receive the investigational GSK3390107A (ChAd3-EBO-Z)
vaccine (provided that no safety concerns are raised), whereas the children in the Group
GSK3390107A+Nimenrix will receive Nimenrix.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
| Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
| Completed |
NCT04644484 -
A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety
|
Phase 3 | |
| Completed |
NCT00984945 -
Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults
|
Phase 1 | |
| Completed |
NCT00734175 -
Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine
|
Phase 1 | |
| Completed |
NCT00516035 -
Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults
|
Phase 1 | |
| Active, not recruiting |
NCT05284097 -
Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study
|
Phase 2 | |
| Completed |
NCT03739112 -
Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly
|
Phase 3 | |
| Recruiting |
NCT06113757 -
Investigation of Efficacy and Safety of Electrical Signal Therapy Provided by Dr Biolyse® Device in COVID-19 Disease
|
N/A | |
| Completed |
NCT01991587 -
Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults
|
Phase 1/Phase 2 | |
| Completed |
NCT03294135 -
The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine
|
Phase 4 | |
| Active, not recruiting |
NCT02545517 -
A Clinical Study to Evaluate Immune Responses to Rabies Vaccine in Adults Who Received Different Primary Rabies Vaccination Regimens
|
Phase 3 | |
| Active, not recruiting |
NCT05619770 -
Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects
|
Phase 1 | |
| Not yet recruiting |
NCT01289301 -
Studying the Effect of Changing Immunosuppression in Case of Polyoma BK Virus Infection of the Renal Transplant
|
Phase 4 | |
| Active, not recruiting |
NCT01055990 -
Basic and Clinical Research on Applying Blood Fix to Treat Critical H1N1 Patients
|
Phase 2 | |
| Completed |
NCT01842997 -
Safety of H1N1 Influenza Vaccination in Pregnant Women
|
Phase 4 | |
| Completed |
NCT00980447 -
Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults
|
Phase 2 | |
| Completed |
NCT00380237 -
Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B)
|
Phase 1 | |
| Completed |
NCT00219453 -
Pilot Safety Study to Determine the Ability of the Protector Cap Jet Injector to Prevent Cross-Contamination
|
Phase 1 | |
| Completed |
NCT01480258 -
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
|
Phase 3 |